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Objective: To evaluate the impact of using network meta-analysis (NMA) versus pair wise meta-analyses (PMA) for
evidence synthesis on key outputs of cost-effectiveness analysis (CEA).
Methods: We conducted Bayesian NMA of randomized clinical trials providing head-to-head and placebo comparisons
of the effect of pharmacotherapies on the exacerbation rate in chronic obstructive pulmonary disease (COPD). Separately,
the subset of placebo–comparison trials was used in a Bayesian PMA. The pooled rate ratios (RR) were used to populate a
decision-analytic model of COPD treatment to predict 10-year outcomes.
Results: Efficacy estimates from the NMA and PMA were similar, but the NMA provided estimates with higher precision.
This resulted in similar incremental cost-effectiveness ratios (ICER). Probabilities of being cost-effective at willingness-to-pay
thresholds (WTPs) between $25,000 and $100,000 per quality adjusted life year (QALY) varied considerably between the
PMA- and NMA-based approaches. The largest difference in the probabilities of being cost-effective was observed at a
WTP of approximately $40,000/QALY. At this threshold, with the PMA-based analysis, ICS, LAMA and placebo had a 43%,
30, and 18% probability of being the most cost-effective. By contrast, with the NMA based approach, ICS, LAMA, and
placebo had a 56%, 19%, and 21% probability of being cost-effective. For larger WTP thresholds the probability of LAMA
being the most cost-effective became higher than that of ICS. Under the PMA-based analyses the cross-over occurred at
a WTP threshold between $60,000/QALY-$65,000/QALY, whereas under the NMA-based approach, the cross-over occurred
between $85,000/QALY-$90,000/QALY.
Conclusion: Use of NMAs in CEAs is feasible and, as our case study showed, can decrease uncertainty around
key cost-effectiveness measures compared with the use of PMAs. The approval process of health technologies in
many jurisdictions requires estimates of comparative efficacy and cost-effectiveness. NMAs play an increasingly
important role in providing estimates of comparative efficacy. Their use in the CEAs therefore results in methodological
consistency and reduced uncertainty.
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Network meta-analysis (NMA) (also known as multiple
or mixed treatment comparisons) are becoming widely
accepted for establishing comparative efficacy between
competing health technologies [1-4]. In contrast with
conventional pair wise meta-analysis (PMA), NMAs
allow for comparisons between interventions that have
not been compared head-to-head in randomized clin-
ical trials (RCTs), and offer additional precision by
‘borrowing strength’ from indirect evidence [1,2,5-7].
In medical decision-making, NMAs are commonly
used in health technology assessments produced by
government agencies or pharmaceutical companies
in connection with technology approval submissions
[8-10]. In this context, NMAs can provide reliable and
consistent evidence on the efficacy and safety of the
considered interventions. The contemporary technol-
ogy approval process in many jurisdictions is informed
by evaluating comparative efficacy as well as cost-
effectiveness analysis (CEA) comparing the new technol-
ogy with the alternative choices. NMAs are increasingly
popular frameworks for synthesizing evidence on com-
parative efficacy [2,3]. Despite the merits of NMAs, it is
still common that evidence synthesis for the CEA is based
on conventional PMA meta-analysis. While some integra-
tion of NMAs and CEAs are beginning to take place
in commercially prepared health technology assessment
(HTA) reports, we are not aware of any published applica-
tions intended to inform decision-making.
In addition, it is well accepted that CEAs should be
comprehensive [11]. That is, the analysis should include
all available treatment options; and the evidence synthe-
sis should be based on all the available evidence [12]. A
CEA based on PMA meta-analyses may however fall
short in these two aims. First, evidence on comparative
efficacy and safety may not be available for all treatments
via PMA meta-analysis because not all options have
been compared head-to-head or with a common control
intervention. Second, when more than two options are
compared, the evidence synthesis for a PMA is often
based on taking one technology as the ‘reference’ and
looking for comparative studies of other technologies
with that reference. In this vein, head-to-head compari-
sons between the considered interventions, as well as
relevant comparisons with older interventions might be
discarded, and so the full evidence-base is not utilized in
the CEA. NMAs on the other hand can produce esti-
mates of comparative efficacy for all considered options,
and allow for inclusion of all relevant randomized evi-
dence (i.e., both direct and indirect evidence). Therefore
NMAs are likely to more optimally and rationally utilize
the available evidence, and the resulting added precision
and accuracy may translate into a more confident adop-
tion decision.The use of PMAs rather than NMAs for evidence syn-
thesis in economic evaluations therefore represents a
missed opportunity for optimizing decision-making [5].
To provide insights on the benefit of using NMAs, ra-
ther than PMAs, in CEAs we use an illustrative case of
pharmacotherapies for chronic obstructive pulmonary
disease (COPD). We demonstrate how the precision
gained on efficacy estimated via the NMA, as opposed to
PMA, can reduce the uncertainty around CEA outputs and
can result in more confident adoption decisions. We also
provide practical guidance on the step-wise processes
needed to incorporate the NMA analysis into the CEA
process.Methods and material
We use a motivating example of pharmacotherapies for
the treatment of moderate to severe of COPD. COPD is
a chronic disease of the airways that is responsible for a
substantial economic and humanistic burden [13]. Exac-
erbations (lung attacks) are hallmarks of COPD, and are
associated with significant costs, impaired quality of life,
and risk of mortality [14]. There are multiple pharmaco-
therapies available for COPD and there is considerable
debate on which pharmacotherapy should be used as
first line treatment in COPD [15]. There is inconsistent
evidence as to whether pharmacotherapies can change
the course of COPD. Nevertheless, pharmacotherapies
have a proven impact on reducing the exacerbation rate
in COPD [16]. There are several RCTs comparing such
therapies with placebo (i.e., no treatment), as well as a
large number of RCTs providing head-to-head compari-
sons between such therapies [16].NMA model and data
Efficacy data was taken from a recent NMA on the effect
of pharmacotherapies in reducing the exacerbation rates
in patients with COPD [16]. In particular, five interven-
tions were considered: no treatment (placebo), inhaled
corticosteroids (ICS), long-acting beta-agonists (LABA),
long-acting muscarinic agents (LAMA), and the combin-
ation of ICS and LABA (ICS + LABA). Several agents are
available within each of these three drug classes (e.g.,
salmeterol, formoterol, and indacaterol are all LABAs)
but they were considered equally effective in this ana-
lysis. While some may challenge this assumption, there
are a number of reasons for employing this assumption
in our study. First, our study is predominantly of an edu-
cational nature, and thus, simplicity in assumptions is
key. Second, the NMA on which this study is based also
assumed class-effects [16]. Third, other NMA that have
distinguished between therapies within classes have
failed to demonstrate statistically significant differences
within classes [17]. Lastly, the assumption of ‘class effect’
Abbreviations: ICS (Inhaled Corticosteroids); LABA (Long-acting Beta Agonists); LAMA (Long-acting 
Muscarinic Agents). 
A B
Figure 1 Treatment networks constituting the evidence-base used in the PMA (left) and NMA (right) analyses.
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accepted paradigm in COPD [18].
Details of the NMA are provided elsewhere [16]. The
outcome (effect) of interest in synthesizing such evi-
dence was the impact of the intervention on the yearly
rate of COPD exacerbation. A total of 19 trials (14 two-
arm trials, 1 three-arm trial, and 4 four-arm trials)
including a total of 28,172 patients informed the
evidence-base. Most interventions had been compared
head-to-head in at least one RCT. The effect measure of
the NMA was the rate ratio (RR) comparing each treat-
ment versus no treatment (i.e., placebo) for yearly inci-
dence rates of exacerbations (an RR less than one means
the treatment reduced the exacerbation rate, compared
with no treatment). One-year RR estimates were ob-
tained using a Bayesian Poisson regression NMA model
[10]. Separately, Bayesian Poisson regression PMAs were
used to obtain conventional pair wise RRs for each of
the considered interventions versus no treatment, fromFigure 2 Markov model used for the performed cost-effectiveness anthe placebo-based RCTs. Figure 1(A) presents the treat-
ment network of available comparisons, and Figure 1(B)
presents the full treatment network.
Economic model and data
A decision-analytic model of COPD was created that
translated the measures of treatment effect [16], com-
bined with parameters representing the epidemiology
[13,19] and natural history [20,21] of COPD, into the
costs [22,23], exacerbation rates and quality-adjusted life
years (QALYs) associated with each treatment [16,20,21].
The time-horizon was 10 years with one-year time cy-
cles. A constant yearly rate of exacerbations was as-
sumed, thus allowing for the NMA RR estimate to be
employed for determining transition probabilities for
each of the ten cycles. Yearly mortality rates were taken
from American life Tables [24]. The yearly discount rate
was set to 3% for both health and cost outcomes. The
analysis adopted a third-party payer perspective. Allalysis.
Table 1 Parameter estimates and their probability distributions used to populate the model
Parameter Assumed input value at GOLD stages Assumed probability distribution at GOLD stages
II III II III
Annual COPD mortality [20] 0.00393 0.006762 – –
Utility and disutilities [19]
Baseline 0.72 0.67 B(160, 62) B(59, 29)
Minor exacerbation 0.658 0.475 B(164, 85) B(47, 52)
Major exacerbation 0.447 0.408 B(22, 27) B(39, 57)
Exacerbations rates and probabilities [19]
Frequency 1.22 1.47 Γ(14884, 12200) Γ(21609, 14700)
Minor (%) 0.93 0.90 Γ(8649, 9300) Γ(8100, 9000)
Major (%) 0.07 0.10 Γ(12.25, 175) Γ(25, 250)
Minor exacerbation 80$ 134$ Γ(320, 4) Γ(536, 4)
Major exacerbation 3250$ 5417$ Γ(13000, 4) Γ(21668, 4)
Indirect maintenance cost [20] 215$ 524$ Γ(860, 4) Γ(2096, 4)
Direct exacerbations costs ($) [19]
Minor exacerbations 161$ Γ(644, 4)
Major exacerbations 6501$ Γ(26004, 4)
General practitioner visit 70$ Γ(280, 4)
Specialist visit 90$ Γ(360, 4)
Direct medication costs ($) [22]
Inhaled corticosteroids (ICS) 450$ –
Long-acting beta-agonists (LABA) 500$ –
ICS + LABA 1000$ –
Long-acting muscarinic agents 750$ –
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year 2011 US dollars ($).
Figure 2 demonstrates the structure of the model. In
modeling the natural history of patients with moderate to
severe COPD, we used the Global Burden of Lung Disease
(GOLD) criteria to classify COPD into mild, moderate, and
severe. However, as the RCTs informing the evidence base
evaluated the impact of treatments in patients with moder-
ate/severe COPD, we excluded the state of mild COPD. InTable 2 Incidence rate ratio estimates for the considered
interventions based on pair-wise meta-analysis (PMA)
and network meta-analysis (NMA)
Intervention Rate ratios (95% CrI)
PMA NMA
Placebo
ICS 0.81 (0.68-0.95) 0.81 (0.72-0.91)
LABA 0.87 (0.75-1.01) 0.87 (0.78-0.96)
ICS + LABA 0.71 (0.60-0.88) 0.70 (0.62-0.79)
LAMA 0.73 (0.59-0.91) 0.74 (0.67-0.82)
PTC: pairwise treatment comparison, MTC: multiple treatment comparison, CrI:
credible interval.addition to COPD states, individuals in the model could
also independently move through the states representing
being a current smoker, ex-smoker, and never-smoker. Indi-
viduals could not revert from a worse COPD state to a bet-
ter COPD state.
Each state of COPD was associated with an annual ex-
acerbation rate for each treatment, which was calculated as
the product of a baseline (no treatment) rate multiplied by
the RR of the treatment versus no treatment. Exacerbations
were categorized as either minor or major. The impact of
treatment was assumed to be independent of the severity of
the exacerbation.
Table 1 provides the parameter estimates and their
probability distributions used to populate the model.
Estimates in original reports for the majority of the pa-
rameters were accompanied by confidence intervals or
standard errors. As such, each parameter was modeled
as a probability distribution to match the reported
level of uncertainty. On the other hand, cost compo-
nents often were not accompanied by uncertainty, and
we a priori decided to model costs to have a gamma
distribution with a coefficient of variation of 0.25. Cost
of medications were assumed fixed at their known
value in 2013.
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The Bayesian NMA model was run in WinBUGS v.1.4.3
[25], and the economic model was run in R v2.14 [26].
WinBUGS and R code is available from the authors upon
request. The step-wise implementation of the PMA and
NMA analyses and the CEA is described further in the
Additional file 1. A total of 10,000 posterior distribution
samples were used for the CEA, separately for the NMA
and PMA meta-analyses. The model outputs on costs and
QALYs were used to calculate the ICERs and incremental
net monetary benefits (INMB), with no treatment as
the reference group, and to draw the cost-effectiveness
planes and cost-effectiveness acceptability curves (CEACs).
Treatments were also ranked according to their INMB at
WTP of $50,000/QALY, separately for PMA- and NMA-
based analyses.
Results
Table 2 presents the RRs and the associated credible in-
tervals (CrI) for all treatment vs no treatment compari-
sons based on the NMA and PMA meta-analyses. The
pooled RR estimates for all treatment vs no treatment
comparisons were similar for the NMA and PMA meta-
analyses, but the NMA results had higher precision,
manifested in terms of tighter CrIs (Table 2).
Table 3 presents the mean and 95% CrIs for costs, ex-
acerbation rates, and QALYs. Figure 3 presents the un-
certainty ellipses around the incremental cost and QALY
estimates on the cost-effectiveness plane. Uncertainty
around both costs and QALYs was reduced substantially
in the NMA-based analysis. This reduction is visually
apparent from the considerably smaller 95% credible
ellipses NMA-based analysis compared with the PMA-
based analysis in Figure 3.
Table 4 presents the ICERs and probabilities of each
treatment being cost-effective as WTP thresholds of
$30,000, $50,000, $70,000, and $100,000. Figure 4
presents the CEACs for all interventions from WTPTable 3 10-year average cost, number of exacerbations, and q
both pairwise meta-analysis (PMA) and network meta-analysi
Intervention Meta-analysis Costs ($)
Placebo PMA 25 458 (19 927, 32 312)
NMA 25 316 (19 950, 31 897)
ICS PMA 27 116 (22 194, 33 307)
NMA 26 979 (21 991, 33 420)
LABA PMA 28 304 (23 081, 34 897)
NMA 28 116 (23 002, 34 604)
ICS + LABA PMA 30 849 (25 947, 36 741)
NMA 30 496 (25 902, 36 133)
LAMA PMA 28 840 (23 928, 35 073)
NMA 28 816 (24 237, 34 548)thresholds between $0/QALY and $100,000/QALY. The
ICERs from the PMA- and NMA-based analyses were
similar, but the probabilities of being cost-effective at the
explored WTP thresholds varied considerably. The
largest difference in the probabilities of being cost-
effective was observed at a WTP of approximately
$40,000/QALY. At this threshold, with the PMA-based
analysis, ICS, LAMA and placebo had a 43%, 30%, and
18% probability of being the most cost-effective. By con-
trast, with the NMA based approach, ICS, LAMA, and
placebo had a 56%, 19%, and 21% probability of being
cost-effective. As illustrated in both Table 4 and Figure 4,
the differences between the two approaches were also
notable for all WTP thresholds above approximately
$25,000. In both analyses, LAMA were estimated more
likely to be cost-effective than ICS for high WTP thresh-
old, but the point where these probabilities crossed were
different between the PMA- and NMA-based analyses.
In particular, with the PMA-based approach the point of
probabilities crossing was between $60,000/QALY and
$65,000/QALY, whereas the point of crossing with the
NMA-based approach was between $85,000/QALY and
$90,000/QALY.
At WTP of $50,000/QALY, the ranking of the first three
treatments (ICS, LAMA, and no treatment) remained the
same between PMA- and NMA-based analyses. The only
difference in the results was that the treatment with the
lowest INMB for the PMA-based analysis was ICS + LABA
whereas for the NMA-based analysis it was LABA.
Discussion
In the present work we elaborated on the theoretical ad-
vantages of using NMAs over PMAs in economic evalu-
ations of health technologies, and used a case study to
demonstrate the practical aspects of the use of NMAs as
well as the empirical differences in the outcomes of the
economic evaluation when NMA instead of PMA is used
for evidence synthesis. The results demonstrate how theuality adjusted life-years for each intervention using
s (NMA)
Number of exacerbations Quality adjusted life years (QALYs)
12.6 (12.5, 12.8) 5.67 (5.36, 5.99)
12.6 (12.5, 12.7) 5.67 (5.34, 5.99)
10.3 (8.62, 11.9) 5.73 (5.40, 6.07)
10.2 (9.10, 11.4) 5.73 (5.38, 6.06)
11.0 (9.31, 13.2) 5.71 (5.39, 6.04)
10.9 (9.86, 12.2) 5.71 (5.37, 6.05)
9.13 (7.69, 11.2) 5.76 (5.42, 6.10)
8.85 (7.83, 10.0) 5.75 (5.40, 6.11)
9.33 (7.47, 11.4) 5.76 (5.42, 6.10)
9.39 (8.37, 10.4) 5.77 (5.41, 6.12)
AB
Abbreviations: QALY (Quality Adjusted Life years; ICS (Inhaled Corticosteroids); 
LABA (Long-acting Beta Agonists); LAMA (Long-acting Muscarinic Agents).  
Figure 3 Cost-effectiveness plane illustrating the 95% credible ellipses for each intervention versus placebo based on the pair wise
meta-analysis (A) and the network meta-analysis (B).
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the entire network of evidence rather than the results of
pair wise comparisons alone. In our case study, while
the added precision did not result in major changes in
the choice of the optimal treatment across a wide rangeof WTP, it prevented the counter-intuitive situation of
the optimal treatment not having the maximum prob-
ability of cost-effectiveness [27].
The network of evidence underlying the case study
was a well-connected treatment network including large




ICER Probability of being cost-effective by willingness-to-pay threshold
$30,000/QALY $50,000/QALY $70,000/QALY $100,000/QALY
Placebo as reference
Placebo PTC Reference 35% 10% 3% 0%
MTC Reference 37% 12% 3% 2%
ICS PTC 27044 40% 42% 38% 31%
MTC 27614 49% 55% 44% 31%
LABA PTC 65509 1% 6% 6% 5%
MTC 64339 1% 2% 1% 0%
ICS + LABA PTC 57933 1% 6% 11% 18%
MTC 52116 0% 7% 1% 29%
LAMA PTC 38427 21% 34% 43% 46%
MTC 41203 13% 24% 35% 38%
ICS as reference
LABA PTC Dominated – – – –
MTC Dominated – – – –
ICS + LABA PTC 89843 – – – –
MTC 96749 – – – –
LAMA PTC 25930 – – – –
MTC 57854 – – – –
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sons. As such, the use of the entire available evidence
base synthesized through NMA resulted in similar point
estimate for the effect size but with an increased preci-
sion. However, situations may occur where NMA esti-
mates are not close to their PMA counterparts; and
where the combination of indirect and direct evidence
does little to increase the precision [7]. However, the
theoretical justifications underpinning the use of NMA
instead of PMA are unrelated to the empirical gains in
certainty and stand valid regardless of any particular
results.
The performed analyses come with some limitations.
We used a simple decision-analytic model of COPD for
the case study, mainly based on the modeling assump-
tions used by previous authors [20,21]. The simplicity of
this model allowed us to focus on the practical aspects
and illustration of the results; but we acknowledge that
to inform policy, a deeper analysis, including a detailed
set of sensitivity and alternative analyses will be required.
For example, our model did not account for the poten-
tial impact of treatments on disease progression [20], a
controversial aspect of the treatment that needs to be
considered in a sensitivity analysis. Our model also did
not account for potential long-term adverse events asso-
ciated with corticosteroid treatment and their associated
costs. However, the complexity of building a decision-model is not intensified by the use of NMA versus PMA
for evidence synthesis.
The implications of the results are rather straightfor-
ward: the potential theoretical and practical gains in
using NMAs as opposed to PMAs in cost-effectiveness
analysis are too significant to be ignored. However, this
does not mean that CEAs should only ever rely on
efficacy estimates from NMAs. NMA is a method of in-
ference and as such is based on certain statistical as-
sumptions that are generally more restrictive than the
assumptions underlying PMA [2,3]. For example, there
are situations where NMA estimates may be more
biased than their PMA counterparts estimated only from
placebo comparisons [28,29]. If in a particular context
where there are misgivings about the suitability of such
assumptions, the investigator might deliberately choose
PMA. Overall, a thorough assessment of the potential
biases and confounders in both the NMA and the PMA
is necessary before deciding which data and type of re-
search synthesis method should be used for informing
the cost-effectiveness analysis.
Conclusion
In summary, incorporating NMA in CEA offers con-
sistency and added certainty in comparison with CEA
informed by conventional PMA. As the role of NMAs in
informing comparative efficacy in the evaluation of new
Abbreviations: WTP (Willingness-to-pay); ICS (Inhaled Corticosteroids); 
LABA (Long-acting Beta Agonists); LAMA (Long-acting Muscarinic Agents). 
A
B
Figure 4 Cost-effectiveness acceptability curves when efficacy results are based on the pair wise meta-analysis (A) and the network
meta-analysis (B).
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be considered for informing the evidence used in CEA.Additional file
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